Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence

References

• Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81(10):928–930.
   PubMed Web of Science ®Google Scholar
• Cohen JI. Clinical practice: herpes zoster. N Engl J Med. 2013;369(3):255–263.
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, McGinnis JJ, Tan L, et al. Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013. J Prim Prev. 2015;36(4):259–273.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Shingles (herpes zoster): overview; 2016 [cited 2020 Sep 23]. http://www.cdc.gov/shingles/about/overview.html
   Google Scholar
• Varghese L, Standaert B, Olivieri A, et al. The temporal impact of aging on the burden of herpes zoster. BMC Geriatr. 2017;17(1):30.
   PubMedGoogle Scholar
• Dooling KL, Guo A, Patel M, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. Am J Transplant. 2018;18(3):756–762.
   Web of Science ®Google Scholar
• Gabutti G, Bolognesi N, Sandri F, et al. Varicella zoster virus vaccines: an update. Immunotargets Ther. 2019;8:15–28.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Vaccines and preventable diseases: what everyone should know about zostavax; 2020 [cited 2021 Jul 15]. https://www.cdc.gov/vaccines/vpd/shingles/public/zostavax/index.html
   Google Scholar
• Chen LK, Arai H, Chen LY, et al. Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific. BMC Infect Dis. 2017;17(1):213.
   PubMedGoogle Scholar
• Piot P, Larson HJ, O'Brien KL, et al. Immunization: vital progress, unfinished agenda. Nature. 2019;575(7781):119–129.
   PubMed Web of Science ®Google Scholar
• Chiyaka ET, Nghiem VT, Zhang L, et al. Cost-Effectiveness of herpes zoster vaccination: a systematic review. Pharmacoeconomics. 2019;37(2):169–200.
   PubMed Web of Science ®Google Scholar
• Crespo C, Monleon A, Díaz W, et al. Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies. BMC Med Res Methodol. 2014;14(1):139.
   PubMed Web of Science ®Google Scholar
• Bagepally BS, Chaikledkaew U, Gurav YK, et al. Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diabetes Res Care. 2020;8(1):e001020.
   PubMed Web of Science ®Google Scholar
• Bagepally BS, Gurav YK, Anothaisintawee T, et al. Cost utility of sodium-glucose cotransporter 2 inhibitors in the treatment of metformin monotherapy failed type 2 diabetes patients: a systematic review and meta-analysis. Value Health. 2019;22(12):1458–1469.
   PubMed Web of Science ®Google Scholar
• Haider S, Chaikledkaew U, Thavorncharoensap M, et al. Systematic review and meta-analysis of cost-effectiveness of rotavirus vaccine in low-income and lower-middle-income countries. Open Forum Infect Dis. 2019;6(4):ofz117.
   PubMed Web of Science ®Google Scholar
• Noparatayaporn P, Thavorncharoensap M, Chaikledkaew U, et al. Incremental net monetary benefit of bariatric surgery: systematic review and meta-analysis of cost-effectiveness evidences. Obes Surg. 2021;31(7):3279–3290.
   PubMed Web of Science ®Google Scholar
• Chaiyakittisopon K, Pattanaprateep O, Ruenroengbun N, et al. Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations. Eur J Health Econ. 2021;22(4):571–584.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Meeting of the immunization and vaccine related Implementation Research Advisory Committee (IVIR-AC). Weekly Epidemiological Record, No 17, 2021, 96, 133–144; 2021 [cited 2021 Jul 15]. https://www.who.int/publications/i/item/weekly-epidemiological-record-no-17-2021-96-133-144
   Google Scholar
• Adarkwah CC, van Gils PF, Hiligsmann M, et al. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):513–523.
   PubMed Web of Science ®Google Scholar
• Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18(2 Suppl):S68–S80.
   PubMed Web of Science ®Google Scholar
• Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, et al. Meta-analysis of economic evaluation studies: data harmonisation and methodological issues. Research Square Web site; 2020 [Updated 2021 Sep 8; cited 2021 Jul 15].
   Google Scholar
• The World Bank. Consumer price index (2010 = 100); 2019 [cited 2020 Oct 8]. https://data.worldbank.org/indicator/FP.CPI.TOTL?end=2014&start=2014&view=map&year=2019
   Google Scholar
• The World Bank. PPP conversion factor, private consumption (LCU per international $); 2019 [cited 2020 Oct 8]. https://data.worldbank.org/indicator/PA.NUS.PRVT.PP?end=2018&start=2018&view=map
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Peters JL, Sutton AJ, Jones DR, et al. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61(10):991–996.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Working with the regions; 2020 [cited 2021 Jan 14]. https://www.who.int/chp/about/regions/en/
   Google Scholar
• Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006;145(5):317–325.
   PubMed Web of Science ®Google Scholar
• Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25(49):8326–8337.
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44(10):1280–1288.
   PubMed Web of Science ®Google Scholar
• Brisson M, Pellissier JM, Camden S, et al. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin. 2008;4(3):238–245.
   PubMed Web of Science ®Google Scholar
• Najafzadeh M, Marra CA, Galanis E, et al. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics. 2009;27(12):991–1004.
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Gay N, Melegaro A, et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27(9):1454–1467.
   PubMed Web of Science ®Google Scholar
• Annemans L, Bresse X, Gobbo C, et al. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ. 2010;13(3):537–551.
   PubMedGoogle Scholar
• Moore L, Remy V, Martin M, et al. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc. 2010;8:7.
   PubMedGoogle Scholar
• van Lier A, van Hoek AJ, Opstelten W, et al. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in The Netherlands. BMC Health Serv Res. 2010;10:237.
   PubMed Web of Science ®Google Scholar
• Szucs TD, Kressig RW, Papageorgiou M, et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin. 2011;7(7):749–756.
   PubMed Web of Science ®Google Scholar
• Bresse X, Annemans L, Préaud E, et al. Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2013;13(3):393–406.
   PubMed Web of Science ®Google Scholar
• de Boer PT, Pouwels KB, Cox JM, et al. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine. 2013;31(9):1276–1283.
   PubMed Web of Science ®Google Scholar
• Ultsch B, Weidemann F, Reinhold T, et al. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res. 2013;13:359.
   PubMed Web of Science ®Google Scholar
• Préaud E, Uhart M, Böhm K, et al. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany. Hum Vaccin Immunother. 2015;11(4):884–896.
   PubMed Web of Science ®Google Scholar
• Le P, Rothberg MB. Cost-Effectiveness of herpes zoster vaccine for persons aged 50 years. Ann Intern Med. 2015;163(7):489–497.
   PubMed Web of Science ®Google Scholar
• Belchior E, Lévy-Bruhl D, Le Strat Y, et al. Cost-effectiveness of a herpes zoster vaccination program among the French elderly people. Hum Vaccin Immunother. 2016;12(9):2378–2382.
   PubMed Web of Science ®Google Scholar
• Bilde L, Nielsen TT, Rønholt F, et al. The cost-effectiveness of introducing a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in elderly Danes. Nordic J Health Eco. 2016;5(2):7–27.
   Google Scholar
• Coretti S, Codella P, Romano F, et al. Cost-effectiveness analysis of herpes zoster vaccination in Italian elderly persons. Int J Technol Assess Health Care. 2016;32(4):233–240.
   PubMed Web of Science ®Google Scholar
• Lopez-Belmonte JL, Cisterna R, Gil de Miguel A, et al. The use of zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older. J Med Econ. 2016;19(6):576–586.
   PubMed Web of Science ®Google Scholar
• Blank PR, Ademi Z, Lu X, et al. Herpes zoster vaccine: a health economic evaluation for Switzerland. Hum Vaccin Immunother. 2017;13(7):1495–1504.
   PubMed Web of Science ®Google Scholar
• Hoshi SL, Kondo M, Okubo I. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan. Vaccine. 2017;35(24):3264–3271.
   PubMed Web of Science ®Google Scholar
• Pan J, Hsu T, Johnson KD, et al. Cost-effectiveness analysis of herpes zoster vaccine in adults above 50 in Singapore. Dermatol Sin. 2017;35(4):177–181.
   Web of Science ®Google Scholar
• Le P, Rothberg MB. Determining the optimal vaccination schedule for herpes zoster: a cost-effectiveness analysis. J Gen Intern Med. 2017;32(2):159–167.
   PubMed Web of Science ®Google Scholar
• Le P, Rothberg MB. Cost effectiveness of a shingles vaccine booster for currently vaccinated adults in the U.S. Am J Prev Med. 2017;53(6):829–836.
   PubMed Web of Science ®Google Scholar
• Carpenter CF, Aljassem A, Stassinopoulos J, et al. A cost-effectiveness analysis of an adjuvanted subunit vaccine for the prevention of herpes zoster and post-herpetic neuralgia. Open Forum Infect Dis. 2019;6(7):ofz219.
   PubMed Web of Science ®Google Scholar
• Curran D, Patterson B, Varghese L, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36(33):5037–5045.
   PubMed Web of Science ®Google Scholar
• Curran D, Patterson BJ, van Oorschot D, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. Hum Vaccin Immunother. 2019;15(4):765–771.
   PubMed Web of Science ®Google Scholar
• de Boer PT, van Lier A, de Melker H, et al. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in The Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines. BMC Med. 2018;16(1):228.
   PubMedGoogle Scholar
• Drolet M, Zhou Z, Sauvageau C, et al. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study. CMAJ. 2019;191(34):E932–E939.
   PubMed Web of Science ®Google Scholar
• Hoshi SL, Seposo X, Shono A, et al. Cost-effectiveness of recombinant zoster vaccine (RZV) and varicella vaccine live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan. Vaccine. 2019;37(27):3588–3597.
   PubMed Web of Science ®Google Scholar
• McGirr A, Van Oorschot D, Widenmaier R, et al. Public health impact and cost-effectiveness of non-live adjuvanted recombinant zoster vaccine in Canadian adults. Appl Health Econ Health Policy. 2019;17(5):723–732.
   PubMed Web of Science ®Google Scholar
• Melegaro A, Marziano V, Del Fava E, et al. The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study. BMC Med. 2018;16(1):117.
   PubMedGoogle Scholar
• Prosser LA, Harpaz R, Rose AM, et al. A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations. Ann Intern Med. 2019;170(6):380–388.
   PubMed Web of Science ®Google Scholar
• Shiragami M, Mizukami A, Kaise T, et al. Cost-effectiveness of the adjuvant recombinant zoster vaccine in Japanese adults aged 65 years and older. Dermatol Ther. 2019;9(2):281–297.
   PubMed Web of Science ®Google Scholar
• Van Oorschot D, Anastassopoulou A, Poulsen Nautrup B, et al. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old. Hum Vaccin Immunother. 2019;15(1):34–44.
   PubMed Web of Science ®Google Scholar
• You JHS, Ming WK, Lee CF, et al. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong. Vaccine. 2018;36(31):4610–4620.
   PubMed Web of Science ®Google Scholar
• You JHS, Ming WK, Tsang OT, et al. Optimal gender-specific age for cost-effective vaccination with adjuvanted herpes zoster subunit vaccine in Chinese adults. PLOS One. 2019;14(1):e0210005.
   PubMed Web of Science ®Google Scholar
• Lecrenier N, Beukelaers P, Colindres R, et al. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Rev Vaccines. 2018;17(7):619–634.
   PubMed Web of Science ®Google Scholar
• Kim DK, Riley LE, Hunter P, et al. Recommended immunization schedule for adults aged 19 years or older, United States, 2018. Ann Intern Med. 2018;168(3):210–220.
   PubMed Web of Science ®Google Scholar
• Marra F, Parhar K, Huang B, et al. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020;7(1):ofaa005.
   PubMed Web of Science ®Google Scholar
• Willan AR. Incremental net benefit in the analysis of economic data from clinical trials, with application to the CADET-Hp trial. Eur J Gastroenterol Hepatol. 2004;16(6):543–549.
   PubMed Web of Science ®Google Scholar
• Willan AR, Lin DY. Incremental net benefit in randomized clinical trials. Stat Med. 2001;20(11):1563–1574.
   PubMed Web of Science ®Google Scholar